Summary of Use during Lactation

No information is available on the use of bendamustine during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as bendamustine.[1] The manufacturer recommends that breastfeeding be discontinued during bendamustine therapy. Based on the half-life of the drug and its metabolites, the drug should be eliminated from the milk by 24-48 hours after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Some evidence indicates that carmustine can increase serum prolactin.[2]

Substance Name

Bendamustine

CAS Registry Number

16506-27-7

Drug Class

• Breast Feeding
• Lactation
• Antineoplastic Agents, Alkylating
• Nitrosourea Compounds